Pliant Therapeutics Announces Executive and Director Changes
Ticker: PLRX · Form: 8-K · Filed: Oct 24, 2025 · CIK: 1746473
| Field | Detail |
|---|---|
| Company | Pliant Therapeutics, Inc. (PLRX) |
| Form Type | 8-K |
| Filed Date | Oct 24, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
Related Tickers: PLRX
TL;DR
Pliant Therapeutics (PLRX) shakes up its board and exec pay. Big changes effective Oct 20.
AI Summary
Pliant Therapeutics, Inc. announced on October 20, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for its key executives. These changes are effective as of October 20, 2025.
Why It Matters
Changes in leadership and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with compensatory arrangements, can indicate internal shifts that may affect future performance and strategy.
Key Players & Entities
- PLIANT THERAPEUTICS, INC. (company) — Registrant
- October 20, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 331 Oyster Point Blvd., South San Francisco (address) — Business Address
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates the departure of certain officers and directors, but does not specify the exact roles affected in this summary.
Who are the newly elected directors?
The filing states that new directors have been elected, but their names are not provided in this summary.
What are the details of the compensatory arrangements for certain officers?
The filing mentions adjustments to compensatory arrangements for certain officers, but the specific details are not included in this summary.
What is the effective date of these changes?
The changes reported in this 8-K filing are effective as of October 20, 2025.
What is the primary business of Pliant Therapeutics, Inc.?
Pliant Therapeutics, Inc. is in the business of Pharmaceutical Preparations, as indicated by its SIC code [2834].
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 11.7 · Accepted 2025-10-24 16:32:41
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share PLRX The Nasdaq Stock Market
Filing Documents
- plrx-20251020.htm (8-K) — 26KB
- 0001746473-25-000159.txt ( ) — 186KB
- plrx-20251020.xsd (EX-101.SCH) — 3KB
- plrx-20251020_def.xml (EX-101.DEF) — 16KB
- plrx-20251020_lab.xml (EX-101.LAB) — 29KB
- plrx-20251020_pre.xml (EX-101.PRE) — 17KB
- plrx-20251020_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. PLIANT THERAPEUTICS, INC. Date: October 24, 2025 By: /s/ Keith Cummings Keith Cummings, M.D., MBA Chief Financial Officer